A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 493 participants.

Also called NCT02302716

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 493 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02302716
Other papers using this trial's data
  • Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study Clinical drug investigation, 2019-08 DOI, PubMed 31119716, PMC6656918 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, India, Puerto Rico, Russia, South Korea, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02302716. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2017-10-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
Acronym
ELEMENT 5
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2963016
Intervention (Drug)
LANTUS®
Intervention (Drug)
Oral Antihyperglycemic Medication
Lead sponsor
Eli Lilly and Company (class: industry)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct02302716
Content hash
25d0bbebe3bc8e0b47d83d417b704f4403203bee3ae27f8ce8d4c315cd2b5429